Pharmaceuticals

USPTO-FDA Study Debunks Critics and Demonstrates the Importance of Protecting IP
USPTO-FDA study reinforces the need to protect pharmaceutical intellectual property rights for the future of new drug development.

New Study Shows PBMs Lower Drug Prices
A new report challenges assertions made during the committee's recent hearing on the role of pharmacy benefit managers.

The Senate Must Reject Price Controls on Pharmaceuticals
Senators should reject price controls on pharmaceuticals; they will not lower prices and lead to fewer future cures.

Congress Should Listen to Voters and Reject Drug Price Controls
A message was sent by voters in Virginia, New Jersey, and New York last night. Is Congress listening?

No Government Price Controls to Pay for Biden’s Gargantuan Spending Bill
Sen. Ron Wyden (D-Ore.) wants to use price controls in Medicare Part D to pay for President Biden's extravagant spending.

President Biden's Executive Order Will Harm Rather than Promote Competition
President Biden's Executive Order will harm competition and increase the size, scope, and power of the federal government.

Presidential Executive Orders Will Not Lower Drug Costs
On Friday, July 24, President Trump discussed his four Executive Orders that he claims will lower drug costs. They will not.

Wasteful Spending on 340B Keeps Growing and Growing
Amid the COVID-19 pandemic response, the 340B drug safety-net program problems seem to have gotten lost.

Made in America and Wherever Else It May Be Necessary
There have been urgent calls to require pharmaceutical and medical device manufacturers to create all their products in the U.S. – but is that wise?

Healthcare Ready – What it Is and What it Does
Healthcare Ready, a non-governmental organization, is helping to coordinate collaboration to fight the coronavirus.

No Patents = No Drugs or Medical Devices
This is not the time to promote a radical agenda to take advantage of the coronavirus crisis.

Now is Not the Time to Disrupt Medical Supply Chains with Buy American Policies
When the nation is in the middle of an unprecedented public health crisis, it is not the time to impose restrictions on federal agency purchases.